In one small-scale in vitro screen, 21 clinically relevant cancer drugs were tested alone or in combination with MEK or PI3K inhibitors in both 2D and 3D cultures of NF1-deficient HGG cells [140]. This evidence concerns the gene MAP2K7 and cancer.